Carol L. Shields MD
Director, Ocular Oncology Service, Wills Eye Hospital; Professor of Ophthalmology, Sidney Kimmel Medical School of Thomas Jefferson University, Philadelphia, PennsylvaniaDr. Shields graduated from University of Pittsburgh Medical School with highest honors. She is a recipient of the American Academy of Ophthalmology Honor Award and the only female ophthalmologist in the world to receive the prestigious Donders Medal for excellence in ophthalmology from the Dutch Ophthalmologic Society in 2003.Dr. Shields maintains a rewarding professional life managing patients with cancer of the eye. Her special interests include pediatric eye cancer such as retinoblastoma as well as adult eye cancer such as intraocular melanoma, conjunctival tumors and orbital tumors. She has contributed extensively in the field of retinoblastoma with research regarding risks for tumor spread as well as clinical advancements for tumor treatment. Dr. Shields has pioneered the use of newer, naturally moving orbital implants after enucleation of the eye.
Her innovative ideas have allowed many children to have their lives saved and in many cases maintain vision in an eye that had been afflicted with cancer. She is a proponent of early treatment for intraocular melanoma and has been able to save many eyes with this disease using radiotherapy, resection and thermotherapy. Dr. Shields’ extensive knowledge of “cutting edge” ocular technology has propelled the Oncology Service to the forefront of treatment options for our patients.Dr. Carol Shields has contributed over 700 articles in the medical literature regarding eye cancer. She has published nearly 200 chapters in various textbooks and has co-authored five textbooks on ocular tumors. She serves on the editorial board of several ophthalmic journals and has lectured extensively giving over 375 scientific and named lectures.In addition to her nationally recognized practice, she provides care for over 50 new international patients each year from many countries in South America, Europe, Asia and Africa.
Recent Contributions to PracticeUpdate:
- Prognostic Implications of Tenascin C Levels in Peripheral Blood and Primary Tumours at the Time of Uveal Melanoma Diagnosis
- Primary Cemiplimab Treatment for Orbital Squamous Cell Carcinoma Is Effective and May Alleviate the Need for Orbital Exenteration
- Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients With Uveal Melanoma
- Efficacy of Immune Checkpoint Inhibitors for the Treatment of Patients With Periorbital Squamous Cell Carcinoma
- Clinical Characteristics and Outcomes Associated With Different Intraepithelial Growth Patterns in Patients With Eyelid Sebaceous Carcinoma
- Imaging Biomarkers of Leukaemic Choroidopathy Before and After Disease Remission
- Outcomes of Robotic CyberKnife Radiosurgery in Patients With Choroidal and Ciliary Body Melanomas
- Utility of Conjunctival Map Biopsy in Primary Acquired Melanosis/Melanoma
- Aqueous Humor as a Surrogate Biomarker for Retinoblastoma Tumor Tissue
- Prognostic Factors for Survival in Melanoma of the Eyelid